CYP27A1 and metabolic bone disorder: BTMs are a useful adjunct for the diagnosis and therapeutic monitoring of bone metabolic disorders (Greenblatt et al., 2017) The bone resorption marker CTX was significantly decreased in the HMs plus ALE group compared to the ALE group.